Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexandra Kidd

Gynecology Scottsdale, AZ Medical Doctor

NPI 1184717845 CMS profile 235801

10210 N 92Nd St, Suite 201, Scottsdale, AZ 85258

Open in the dashboard

General payments

$6,033

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Kidd of Scottsdale, AZ is reported in the CMS Open Payments database as having received $6,033 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $616 25
2024 General $2,065 33
2023 General $860 45
2022 General $712 30
2021 General $430 23
2020 General $476 26
2019 General $874 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Kidd
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Alexandra Kidd were reported at $616. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Alexandra Kidd Gynecology median Middle half National median
2019 $874 $199 $66–$472 $163
2020 $476 $114 $42–$287 $114
2021 $430 $141 $42–$430 $132
2022 $712 $173 $52–$532 $149
2023 $860 $170 $57–$501 $160
2024 $2,065 $157 $50–$424 $164
2025 $616 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $1,842 11 payments
  2. AbbVie, Inc. $537 31 payments
  3. Hologic, LLC $442 24 payments
  4. Minerva Surgical, Inc $371 4 payments
  5. Millicent US Inc $341 17 payments
  6. Sumitomo Pharma America, Inc. $269 20 payments
  7. TherapeuticsMD, Inc. $232 15 payments
  8. Astellas Pharma US Inc $218 11 payments
  9. Mayne Pharma Inc. $209 7 payments
  10. Merck Sharp & Dohme Corporation $163 7 payments
  11. Other $1,408 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,651 204 payments
  2. Travel and Lodging $1,232 5 payments
  3. Education $141 4 payments
  4. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,842 11 payments
  2. LILETTA $371 20 payments
  3. MYFEMBREE $308 22 payments
  4. LO LOESTRIN FE $263 18 payments
  5. Veozah $218 11 payments
  6. FEMRING $194 11 payments
  7. INTRAROSA $169 11 payments
  8. ANNOVERA $149 10 payments
  9. Endometrial Ablation System (Device) $143 2 payments
  10. Prolia $128 2 payments
  11. Other $2,482 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

393

Median for Obstetrics & Gynecology: 65

Drug cost

$20,261

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

45.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 133 $8,543
Yuvafem Estradiol Brand 17 $2,807
Estradiol (Twice Weekly) Estradiol Brand 30 $2,211
Estradiol (Once Weekly) Estradiol Brand 15 $1,989
Progesterone Progesterone, Micronized Brand 49 $1,790
Clindamycin Phosphate Generic 20 $1,066
Valacyclovir Valacyclovir Hcl Brand 21 $786
Risedronate Sodium Generic 13 $365
Scopolamine Generic 18 $350
Ondansetron Odt Ondansetron Brand 31 $165

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$135,570

Medicare's payments for the services billed

Medicare patients

561

Average age 73

Services billed

1,544

561 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 53%
High blood pressure 49%
Osteoporosis 28%
Ischemic heart disease 18%
Depression 17%
Diabetes 12%
Chronic kidney disease 10%
Cancer 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $89
  • PFIZER INC. $5
$94 — —
Veozah
  • Astellas Pharma US Inc $72
$72 — —
FEMRING
  • MILLICENT US INC $27
$27 — —
INTRAROSA
  • MILLICENT US INC $27
$27 — —
LO LOESTRIN FE
  • AbbVie, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record